ZEB1 Expression in Endometrial Biopsy Predicts Lymph Node Metastases in Patient with Endometrial Cancer

Gang Feng,Jiansheng Zhu,Xiangming Wang,Xiaozhi Cao,Lijuan Shen

doi:10.1155/2014/680361

Abstract

Purpose. The purpose of this study was to analyze the expression of zinc-finger E-box-binding homeobox 1 (ZEB1) in endometrial biopsy and its correlation with preoperative characteristics, including lymph node metastases in patient with endometrial cancer. Methods. Using quantitative RT-PCR, ZEB1 expressions in endometrial biopsy from 452 patients were measured. The relationship between ZEB1 expression and preoperative characteristics was analyzed. Results. ZEB1 expressions were significantly associated with subtype, grade, myometrial invasion, and lymph node metastases. Lymph node metastases could be identified with a sensitivity of 57.8% at specificity of 74.1% by ZEB1 expression in endometrial biopsy. Based on combination of preoperative characteristics and ZEB1 expression, lymph node metastases could be identified with a sensitivity of 62.1% at specificity of 96.2% prior to hysterectomy. Conclusion. ZEB1 expression in endometrial biopsy could help physicians to better predict the lymph node metastasis in patients with endometrial cancer prior to hysterectomy.

Highlights

Endometrial cancer is the most common malignancy of the female reproductive tract and the fourth most common cancer overall [1]
We evaluated whether zinc-finger E-box-binding homeobox 1 (ZEB1) expression in endometrial biopsy could predict lymph node metastases in patients with endometrial cancer
The ZEB1 expression in endometrial biopsy significantly associated with subtype (P = 0.031), grade (P = 0.022), and myometrial invasion (P = 0.014)

Summary

Introduction

Endometrial cancer is the most common malignancy of the female reproductive tract and the fourth most common cancer overall [1]. The incidence of endometrial cancer is rising due to the global obesity epidemic, increased life expectancy, and the falling rate of hysterectomy for benign disease [2]. Disease progression is usually slow, especially for endometrioid adenocarcinoma. The disease has a good prognosis [3]. Endometrial cancer is usually successfully treated with surgery and/or radiotherapy. For patients with advanced or recurrent endometrial cancer, fewer treatment options are available [4]

Objectives

Methods

Results

Conclusion